
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current 0RKL market cap is 3.35B. The company's latest EPS is SEK 5.4438 and P/E is 19.47.
Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
Total Revenue | 179.86M | 258.39M | 415.29M | 597.54M | 822.42M |
Operating Income | -44.19M | -18.74M | 4.46M | 5.4M | 88.35M |
Net Income | -43.74M | 8.15M | 18.43M | 91.82M | 172.18M |
Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
Total Assets | 1.15B | 1.54B | 1.73B | 2.2B | 2.4B |
Total Liabilities | 141.85M | 257.15M | 302.95M | 250.57M | 245.97M |
Total Equity | 1.01B | 1.29B | 1.43B | 1.95B | 2.16B |
Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
Operating | -12.27M | -12.06M | 27.86M | 46.29M | 111.29M |
Investing | -266.53M | -187.7M | -197.62M | -161.62M | -243.81M |
Financing | 482.77M | 234.61M | -6.84M | 418.55M | -10.9M |
Market Cap | 3.35B |
Price to Earnings Ratio | 19.47 |
Price to Sales Ratio | 4.08 |
Price to Cash Ratio | 8.07 |
Price to Book Ratio | 1.55 |
Dividend Yield | - |
Shares Outstanding | 31.63M |
Average Volume (1 week) | 968 |
Average Volume (1 Month) | 1.37k |
52 Week Change | 0.00% |
52 Week High | 106.00 |
52 Week Low | 106.00 |
Spread (Intraday) | 0 (0%) |
Company Name | Xvivo Perfusion Ab |
Address |
massans gata 10 goteborg SE-400 14 |
Website | https://www.xvivoperfusion.com |
Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions